Evaluation of malignancy and prognosis of gastrointestinal stromal tumors: A review

Human Pathology

Volumn 33, Issue 5, 2002, Pages 478-483

  Miettinen, Markku ^a,b   El Rifai, Wa’El ^a,b   Sobin, Leslie ^a,b   Lasota, Jerzy ^a,b  

^a ARMED FORCES INSTITUTE OF PATHOLOGY   (United States)

^b UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

Allelic losses; Gastrointestinal stromal tumor; KIT mutation; Prognosis; Sarcoma

Indexed keywords

IMATINIB; STEM CELL FACTOR;

BENIGN TUMOR; CANCER LOCALIZATION; CONFERENCE PAPER; DIFFERENTIAL DIAGNOSIS; GASTROINTESTINAL TUMOR; GENE MUTATION; HUMAN; MALIGNANT NEOPLASTIC DISEASE; METASTASIS; ONCOGENE C KIT; PROGNOSIS; STROMA; TUMOR DIAGNOSIS; TUMOR VOLUME;

EID: 0036301863     PISSN: 00468177     EISSN: None     Source Type: Journal    
DOI: 10.1053/hupa.2002.124123     Document Type: Article

References (63)

1. Molecular pathology of c-kit proto-oncogene and development of gastrointestinal stromal tumors
2. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors
3. Gastrointestinal stromal tumors: Definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis
4. Gastrointestinal pacemaker cell tumor (GIPACT): Gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal
5. Gastrointestinal autonomic nerve tumor: Immunohistochemical and molecular identity with gastrointestinal stromal tumor
6. Gastrointestinal stromal tumors, intramural leiomyomas, and leiomyosarcomas in the rectum and anus: A clinicopathologic, immunohistochemical and molecular genetic study of 144 cases
7. Effect of tyrosine kinase inhibitor STI-571 in a patient with a metastatic gastrointestinal stromal tumor
8. Evaluation of the safety and efficacy of an oral molecularly-targeted therapy, STI-571, in patients with unresectable or metastatic gastrointestinal stromal tumors (GISTS) expressing c-kit (CD117)
9. Safety and efficacy of imatinib (STI-571) in metastatic gastrointestinal stromal tumors: A phase I study
10. Prognostic factors influencing survival in gastrointestinal leiomyosarcomas: Implications for surgical management and staging
11. Two hundred gastrointestinal stromal tumors: Recurrence patterns and prognostic factors for survival
12. Immunohistochemical spectrum of GISTs at different sites and their differential diagnosis with a reference to CD117 (KIT)
13. Mesenchymal tumors of the gut: Histological perspectives, new approaches, new results, and does it make any difference
14. Esophageal stromal tumors: A clinicopathologic, immunohistochemical, and molecular genetic study of 17 cases and comparison with esophageal leiomyomas and leiomyosarcomas
15. A clinicopathologic and immunohistochemical study of gastrointestinal stromal tumors
16. Prognosis of gastrointestinal smooth-muscle (stromal) tumors: Dependence on anatomic site
17. Cellular leiomyomas of the stomach in 49 patients
18. Stromal tumors of the duodenum: A histologic and immunohistochemical study of 20 cases
19. Stromal tumors of jejunum and ileum: A clinicopathologic study of 39 cases
20. Stromal tumors of jejunum and ileum
21. Stromal tumors of the abdominal colon: A clinicopathologic study of 20 cases
22. Gastrointestinal stromal tumors and leiomyosarcomas in the colon: A clinicopathologic, immunohistochemical, and molecular genetic study of 44 cases
23. Gastrointestinal stromal tumors of the appendix: A clinicopathologic and immunohistochemical study of four cases
24. Gastrointestinal stromal tumors/smooth muscle tumors/GISTs in the omentum and mesentery: A clinicopathologic and immunohistochemical study of 26 cases
25. Extragastrointestinal (soft tissue) stromal tumors: An analysis of 48 cases with emphasis on histological predictors of outcome
26. Differentiation and risk assessment of gastrointestinal stromal tumors
27. Gastrointestinal stromal tumors
28. Smooth muscle tumors of the gastrointestinal tract and retroperitoneum
29. Gastric epithelioid leiomyoma and leiomyosarcoma (leiomyoblastoma)
30. Smooth muscle tumors of the gastrointestinal tract: A study of 56 cases followed for a minimum of 10 years
31. Immunophenotype, proliferation, DNA-ploidy, and biological behavior of gastrointestinal stromal tumors: A multivariate clinicopathologic study
32. Predicting metastatic risk of gastrointestinal stromal tumors: Role of cell proliferation and cell cycle regulatory proteins
33. Ki-67 (MIB-1) immunohistochemistry as a prognostic factor in gastrointestinal smooth-muscle tumors
34. Comparative study on the DNA content of leiomyoma, leiomyoblastoma and leiomyosarcoma of the stomach and small intestine
35. Morphometry and cytophotometric assessment of DNA in smooth muscle tumours (leiomyomas and leiomyosarcomas) of the gastrointestinal tract
36. Leiomyosarcomas and benign smooth muscle tumors of the stomach: Nuclear DNA patterns studied by flow cytometry
37. Smooth muscle tumors of the gastrointestinal tract: Flow cytometric quantitation of DNA and nuclear antigen content and correlation with histologic grade
38. Predicting prognosis of gastrointestinal smooth muscle tumors: Role of clinical and histologic evaluation, flow cytometry, and image cytometry
39. A flow cytometric, clinical, and histological study of stromal neoplasms of the gastrointestinal tract
40. Usefulness of nucleolar organizer region staining in gastric myogenic tumors: Correlation with ploidy by DNA flow cytometry
41. Stromal tumours of the gastrointestinal tract: A clinicopathological and ploidy analysis of 33 cases
42. Smooth muscle tumors of the gastrointestinal tract: Analysis of prognostic factors
43. DNA copy number losses in chromosome 14: An early change in gastrointestinal stromal tumors
44. DNA copy number changes in gastrointestinal stromal tumors-A distinct genetic entity
45. Loss of heterozygosity at 1p36 predicts poor prognosis in gastrointrestinal stromal/smooth muscle tumors
46. Consistent DNA losses on the short arm of chromosome 1 in a series of malignant gastrointestinal stromal tumors
47. Chromosomal aberrations in malignant gastrointestinal stromal tumors: Correlation with c-KIT gene mutation
48. Putative chromosomal deletions on 9P, 9Q and 22Q occur preferentially in malignant gastrointestinal stromal tumors
49. DNA sequence copy number changes in gastrointestinal stromal tumors: Tumor progression and prognostic significance
50. Telomerase and cancer: Time to move from a promising target to a clinical reality
51. Telomarase activity and expression of hTRT and hTR in gastrointestinal stromal tumors in comparison with extragastrointestinal sarcomas
52. Telomerase activity in gastrointestinal stromal tumors
53. KIT extracellular and kinase domain mutations in gastrointestinal stromal tumors
54. KIT activation is ubiquitous feature of gastrointestinal stromal tumors
55. Classes of c-KIT activating mutations: Proposed mechanisms of action and implications in disease classification and therapy
56. Mutations of c-kit JM domain are found in a minority of human gastrointestinal stromal tumors
57. KIT mutation portends poor prognosis in gastrointestinal stromal/smooth muscle tumors
58. Mutations in exon 11 of c-kit occur preferentially in malignant versus benign gastrointestinal stromal tumors and do not occur in leiomyomas or leiomyosarcomas
59. Mutations in exons 9 and 13 of KIT gene are rare events in gastrointestinal stromal tumors: A study of two hundred cases
60. Effect of c-kit mutation on prognosis of gastrointestinal stromal tumors
61. C-kit gene abnormalities in gastrointestinal stromal tumors (tumors of intestitial cells of Cajal)
62. Gain-of-function mutation at the extracellular domain of KIT in gastrointestinal stromal tumours
63. Mutations in c-kit gene exons 9 and 13 in gastrointestinal stromal tumors among Japanese